U.S. Banks Stock News

Alumis Inc. recently reported positive topline Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib in moderate-to-severe plaque psoriasis, where the oral TYK2 inhibitor met all primary and secondary endpoints with high statistical significance versus placebo and an active comparator. By pairing these data with plans for a U.S. FDA New Drug Application in the second half of 2026 and ongoing studies in systemic lupus erythematosus, Alumis is positioning envudeucitinib as a potential...

On 7 January 2026, bp and Corteva announced Etlas, a 50:50 joint venture to produce crop-based feedstock for sustainable aviation fuel and renewable diesel, targeting one million metric tonnes of annual feedstock output by the mid-2030s using intermediate crops grown on existing farmland. The venture highlights how Corteva may link its seed technology with low-carbon fuels, while offering farmers an extra income stream without expanding agricultural land use. Next, we’ll examine how this new...

Super Group (NYSE:SGHC) stock is in focus after the company reported Q3 results, with revenue up 25.7% year on year to US$557 million, beating Wall Street expectations and posting a GAAP profit. See our latest analysis for Super Group (SGHC). Despite the strong Q3 update and plans such as the upcoming Super Coin launch, recent momentum has been weak. The 90 day share price return shows a decline of 22.20%, in contrast with a very strong 1 year total shareholder return of 81.53% and a 3 year...

Insider Buying, Expanded Credit Facility, and Steady Dividend Shape LTC Properties Story LTC Properties (LTC) has drawn fresh attention after its Executive Vice President and Chief Investment Officer, David M. Boitano, bought 10,000 shares and the company expanded its credit facility to US$800 million while reaffirming its monthly dividend. See our latest analysis for LTC Properties. LTC’s recent insider buying, larger credit facility and reaffirmed dividend sit alongside a 7 day share price...

In late 2025, AutoZone reported narrowing profit margins even as its business continued to grow and it pushed ahead with international expansion across the Americas, while keeping a possible move into Europe as a longer-term option. More recently, an analyst downgrade highlighted how AutoZone’s plan to accelerate store openings and build over 160 new distribution hubs could lift operating costs and slow share repurchases, prompting investors to reassess the balance between growth and...

In recent weeks, Guardant Health drew fresh analyst attention after management updates, product expansions in liquid biopsy cancer tests, and new clinical partnerships prompted investors to reassess the business. Beyond near-term excitement, the expansion of Guardant Reveal for advanced solid tumors and the on-site Guardant360 CDx service in Italy highlight how broader clinical adoption could influence the company’s long-term role in cancer care. We’ll now examine how Guardant’s expanded...

Chicago’s congestion surcharge puts Lyft’s pricing and demand in focus Chicago’s new Ground Transportation Tax TNP Congestion Zone Surcharge, which adds per-ride fees in busy areas, puts Lyft (LYFT) under closer scrutiny as investors weigh how higher rider costs could influence demand and overall economics. See our latest analysis for Lyft. While the Chicago surcharge has drawn attention to near term cost pressures, Lyft’s share price return over the past month shows a 12.67% decline...

Leerink Partners’ upgrade of Certara (CERT) to an Outperform rating, after a period of downward revisions, has put fresh attention on the biosimulation specialist and how investors might think about its risk and reward profile. See our latest analysis for Certara. At a share price of $9.49, Certara has recently seen a 7.72% 7 day share price return and a 4.40% 30 day share price return. However, its 1 year total shareholder return of 13.88% and 3 year total shareholder return of 44.41% point...

Event context and recent share performance MakeMyTrip (NasdaqGS:MMYT) has drawn investor attention recently as its share price sits at US$83.19, with a return of about 19% over the past month but a negative move over the past 3 months. See our latest analysis for MakeMyTrip. Looking beyond the recent bounce, MakeMyTrip’s 30 day share price return of 19.1% sits against a 3 month share price decline of 11.9%, while the 1 year total shareholder return of 25.9% decline contrasts with a very large...

Lotus Technology Inc. has replaced its independent auditor, dismissing KPMG Huazhen LLP and appointing Grant Thornton Zhitong Certified Public Accountants LLP to audit its consolidated financial statements for the fiscal year ended December 31, 2025. This shift in audit oversight is important for investors because it can influence confidence in the company’s financial reporting quality and governance practices. We’ll now explore how this auditor change might influence Lotus Technology’s...

Recent commentary on Globant (NYSE:GLOB) has focused on a decline in its return on capital employed over the past five years, even as the company has put more capital to work. See our latest analysis for Globant. Globant's recent 7.63% 7 day share price return and 18.29% 90 day share price return to US$70.36 contrast with a 67.03% 1 year total shareholder return decline. This suggests near term momentum, while longer term returns remain under pressure. If Globant's mixed track record has you...

In recent days, analysts including Evercore ISI have reiterated positive views on UnitedHealth Group’s turnaround, highlighting 2026 as a transition year while investors await the company’s January 27, 2026 release of full-year 2025 results and 2026 guidance. Alongside this renewed analyst optimism, the pending sale of Optum’s UK arm and the appointment of former FDA Commissioner Dr. Scott Gottlieb to the board underscore how UnitedHealth is reshaping its portfolio and governance as it works...

Raymond James recently upgraded Sunoco (SUN) to Strong Buy, and several other brokerages have echoed positive views. This has put fresh attention on what this cluster of analyst moves might mean for the stock. See our latest analysis for Sunoco. At a share price of $53.8, Sunoco has seen a 2.22% 1 day share price return and a 9.95% 90 day share price return. Its 1 year total shareholder return of 9.59% and 5 year total shareholder return of 159.95% suggest momentum that longer term investors...

In late 2025, Flowers Foods reported that it met fourth-quarter earnings guidance and reaffirmed its full-year outlook despite weak bread volumes and rising competition, while also highlighting plans to accelerate innovation and new product launches in 2026 across better-for-you brands like Dave’s Killer Bread and Simple Mills. At the same time, Dave’s Killer Bread expanded deeper into organic, health-focused snacks with new breakfast bars, additional snack bar flavors, and cheese snack...

In early January 2026, Teledyne FLIR OEM, part of Teledyne Technologies, launched Tura™, an automotive-qualified ASIL-B thermal longwave infrared camera built to ISO 26262 functional safety standards for night vision, ADAS, and autonomous vehicles, with high-resolution all-weather imaging and AI-optimized integration. This launch positions Teledyne more firmly in vehicle safety sensing, aligning its thermal imaging capabilities with emerging regulatory requirements such as NHTSA’s FMVSS No...

Why Synchrony Financial Is Back on Investors’ Radar Synchrony Financial (SYF) is drawing fresh attention as investors weigh its recent stock gains, solid earnings profile, and management’s emphasis on disciplined underwriting and active share repurchases. See our latest analysis for Synchrony Financial. Synchrony’s recent share price strength, including a 9.6% 1 month share price return and 23.2% 3 month share price return to US$87.43, sits alongside a 1 year total shareholder return of 35.3%...

In early January 2026, Beam Therapeutics drew fresh attention as Cathie Wood’s ARK Invest accumulated more than 195,000 additional shares while analysts highlighted progress in its precision genetic medicines pipeline, including sickle cell disease and alpha-1 antitrypsin deficiency programs. At the same time, improving sentiment around gene-editing therapies, an upcoming J.P. Morgan Healthcare Conference presentation, and an accelerated regulatory path for Beam’s sickle cell candidate have...

Why the FDA’s priority review for atacicept matters for Vera Therapeutics Vera Therapeutics (VERA) shares are reacting to news that the U.S. FDA accepted the Biologics License Application for atacicept in IgA nephropathy for Priority Review, with a PDUFA target action date of July 7, 2026. See our latest analysis for Vera Therapeutics. The FDA’s Priority Review comes on the back of strong clinical data for atacicept and arrives after a sharp 59.45% 90 day share price return, while the 3 year...

What Humana’s recent performance means for investors Humana (HUM) has drawn fresh attention after recent trading left the shares with a 1 day return of about a 2% decline, while the past week shows roughly 7% growth and the past month about a 7% gain. See our latest analysis for Humana. The recent 7 day share price return of 7.39% and 30 day share price return of 7.28% contrast with a 90 day share price decline of 5.35% and a 3 year total shareholder return loss of 42.35%. This suggests...

Event context and why Commerce Bancshares is on the radar Commerce Bancshares (CBSH) has recently drawn attention after a mixed return pattern, with gains over the past month but a decline over the past 3 months, prompting investors to reassess the bank's current valuation. See our latest analysis for Commerce Bancshares. Stepping back, Commerce Bancshares' 7 day share price return of 2.64% contrasts with a 90 day share price return decline of 3.65% and a 1 year total shareholder return...

Recent analyst upgrades on Trex Company (TREX), combined with insider buying, new distribution partnerships, and a board appointment, have turned fresh attention to the decking maker’s fundamentals after a stretch of industry and share price pressure. See our latest analysis for Trex Company. At a share price of $36.52, Trex’s recent 7 day and 30 day share price returns of 4.10% and 6.35% contrast with a 90 day share price return of 30.42% and a 1 year total shareholder return decline of...

Earlier this week, Baird analyst David George upgraded Simmons First National Corporation to a buy rating, highlighting the bank’s conservative underwriting, stable deposits, and focus on its core community banking franchise across its regional footprint. This endorsement, coupled with generally steady analyst views and ongoing attention to credit quality and funding costs, reinforces Simmons First National’s perception as a comparatively stable income-oriented bank amid cautious sector...

Why the South Lamar opening matters for Life Time Group Holdings Life Time Group Holdings (LTH) has opened its new Life Time South Lamar club in Austin, adding a 57,000-square-foot, two floor location focused on social connection, wellness, and community driven lifestyle experiences. This expansion into a high growth, culturally influential neighborhood gives investors another concrete example of how the company is building out its urban club network. The South Lamar club is designed around...

In early January 2026, Eversource Energy’s NStar Gas reached a rate settlement with the Massachusetts Attorney General, while Connecticut regulators blocked the company’s planned sale of its water utility business, affecting its efforts to simplify operations and address debt. Together, these regulatory outcomes highlight how closely Eversource’s financial flexibility and operational focus depend on state-level decisions about rates and asset divestitures. Next, we’ll examine how...